Publikationsliste
<< Tilbage
« Forrige
1
2
3
4
5
6
Næste »
25. Rodjer S, Nilsson B, Westin J. Do anthracyclines have a role in the therapy of multiple myeloma? Hematol J 2000; 1(6):422-426.
26. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000; 96(9):3139-3146.
27. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95(2):388-392.
28. Wisloff F, Gulbrandsen N. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol 2000; 39(7):809-813.
29. Gulbrandsen N, Wisloff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, Lofvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001; 18(1):65-77.
30. Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 2001; 66(5):328-336.
31. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98(7):2269-2271
32. Seidel C, Bicker G. Developmental expression of nitric oxide/cyclic GMP signaling pathways in the brain of the embryonic grasshopper. Brain Res Dev Brain Res 2002; 138(1):71-79.
Rekvirering